Vimarsana
Biggest News Aggregation in the World

Page 6 - Sciences Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Sciences Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Sciences Group Today - Breaking & Trending Today

US Stocks Mixed; Jobless Claims Fall To 202,000 - E-Home Household Service (NASDAQ:EJH), Avenue Therapeutics (NASDAQ:ATXI) - Vimarsana News

US Stocks Mixed; Jobless Claims Fall To 202,000 - E-Home Household Service (NASDAQ:EJH), Avenue Therapeutics (NASDAQ:ATXI)

U.S. stocks traded mixed this morning, with the Dow Jones index gaining around 50 points on Thursday. Following the market opening Thursday, the Dow traded up 0.15% to 37,487.49 while the NASDAQ fell 0.27% to 14,553.12. The S&P 500 also fell, dropping, 0.01% to 4,704.42.

SELLAS Life Sciences Announces Pricing of $9.0 Million - Vimarsana News

SELLAS Life Sciences Announces Pricing of $9.0 Million

NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical...

Crude Oil Moves Lower; Walgreens Posts Upbeat Earnings - Dyne Therapeutics (NASDAQ:DYN), Avenue Therapeutics (NASDAQ:ATXI) - Vimarsana News

Crude Oil Moves Lower; Walgreens Posts Upbeat Earnings - Dyne Therapeutics (NASDAQ:DYN), Avenue Therapeutics (NASDAQ:ATXI)

U.S. stocks traded mixed toward the end of trading, with the Dow Jones index gaining over 100 points on Thursday. The Dow traded up 0.33% to 37,554.56 while the NASDAQ fell 0.10% to 14,578.04. The S&P 500 also rose, gaining, 0.09% to 4,708.93.

SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma - Vimarsana News

SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma

- Primary Endpoint of Safety and Efficacy Met with Clinical Activity and Increased Survival Observed - - 70.3 Weeks Median Overall Survival for Patients Treated with Combination Therapy; Median...

SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed ... - Vimarsana News

SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed ...

-Primary Endpoint of Safety and Efficacy Met with Clinical Activity and Increased Survival Observed -